Associations of Growth Differentiation Factor 15 in Chronic Kidney Disease Authors: Thomas McDonnell, Samantha Hayward, Nicolas Vuilleumier, Moin A. Saleem, Philip A. Kalra, Maarten W. Taal Published: 2026 ABSTRACT IntroductionAnorexia is common in chronic kidney disease (CKD), yet the underlying mechanisms remain poorly defined. Growth differentiation factor-15 (GDF-15) suppresses appetite in cancer, where anti–GDF-15 therapy improves appetite.MethodsNURTuRE-CKD is a prospective, multicentre cohort study of 2996 individuals with non–dialysis-dependent CKD. At baseline, circulating GDF-15 was measured and appetite was assessed using a questionnaire. Muscle function and estimated muscle mass were evaluated using handgrip strength (kg) and creatinine muscle index (estimated glomerular filtration rate [eGFR] cystatinC × serum creatinine). CKD progression (≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or dialysis initiation) and all-cause mortality were ascertained longitudinally. Multivariable logistic regression evaluated associations between GDF-15 and poor appetite, adjusting for eGFR, urea, nutritional and metabolic markers, CRP, comorbidities, and smoking. Cox models assessed associations with CKD progression (adjusted for Kidney Failure Risk Equation components) and all-cause mortality (additionally adjusted for CRP, comorbidities, and smoking).ResultsGDF-15 was measured in 2929 participants. The median concentration was 2503 pg/ml (interquartile range 1605–3851). Participants with poor appetite (n = 786, 27%) had higher GDF-15 (2965 vs. 2,350 pg/ml; P < 0.001). In adjusted analyses, each doubling of GDF-15 was associated with higher odds of poor appetite (odds ratio [OR] 1.44, 95% CI 1.28–1.62). GDF-15 correlated negatively with handgrip strength (ρ = −0.18; P < 0.001) and creatinine muscle index (ρ= −0.40; P < 0.001), but not with body mass index. Over a median follow-up of 50 (41–56) months, 893 (32%) experienced CKD progression and 527 (18%) died. Adjusted hazard ratios per doubling of GDF-15 were 1.30 (95% CI, 1.18–1.42) for CKD progression and 1.72 (95% CI, 1.58–1.89) for all-cause mortality.ConclusionAmong individuals with non-dialysis CKD, higher circulating GDF-15 concentrations were independently associated with poor appetite, sarcopenia markers, CKD progression, and all-cause mortality. Anorexia, defined as a loss of appetite, is a frequent and clinically significant symptom in chronic kidney disease (CKD). In non–dialysis-dependent CKD, prevalence estimates range from 10% to 50%,1, 2, 3, 4 with higher rates observed at lower levels of kidney function,1,3,5 and in people requiring dialysis.6,7 Anorexia in CKD is associated with reduced quality of life,8 increased hospitalization, and higher mortality.7 Despite its clinical importance, the mechanisms underlying anorexia in CKD remain poorly defined. Proposed explanations have been broad, including systemic inflammation, impaired clearance of middle molecules, or the accumulation of putative anorexigenic compounds.6,9,10 This mechanistic uncertainty has limited the development of effective, targeted therapies, leaving current treatments nonspecific and often ineffective.9 Growth differentiation factor-15 (GDF-15), also known as macrophage inhibitory cytokine-1, is a stress-induced cytokine in the transforming growth factor-β superfamily.11 Experimental tumor models have revealed that GDF-15 drives cancer-associated weight loss through suppression of food intake,12,13 and in 2017, independent groups identified GDF family receptor α-like (GFRAL) and the coreceptor RET as the hindbrain receptors mediating GDF-15’s anorectic effects.14 Ponsegromab, an anti–GDF-15 monoclonal antibody that blocks the GDF-15-GFRAL/RET signaling pathway, has been shown in a randomized trial to significantly improve appetite and body weight in people with cancer-associated cachexia.15 As a stress-responsive cytokine, GDF-15 is upregulated in response to inflammation, ischemia, and tissue injury, and is released from multiple cell types, including renal tubular cells.16,17 GDF-15 has been studied as a risk biomarker in cardiovascular disease and CKD.18 In CKD, circulating GDF-15 increases as estimated glomerular filtration rate (eGFR) declines19 and is associated with higher risks of CKD progression, cardiovascular events, and mortality.20 It remains unclear whether GDF-15 directly exerts deleterious renal effects or reflects underlying disease severity. However, available experimental data suggest that its biological actions are context-dependent. GDF-15–deficient mice develop more severe acute kidney injury, and exogenous GDF-15 administration attenuates fibrosis by reducing fibroblast proliferation and activation.21,22 However, sustained signaling appears maladaptive and profibrotic.16 Although GDF-15 has been studied in relation to CKD progression and mortality, its potential role in mediating anorexia and sarcopenia in CKD remains largely unexplored. We aimed to determine whether circulating GDF-15 concentrations were associated with reduced appetite, sarcopenic indices, and adverse clinical outcomes—specifically CKD progression and all-cause mortality—in a well-characterized, non–dialysis-dependent CKD cohort. Methods Study Population This was an observational analysis of baseline serum GDF-15 concentrations in people with non-dialysis-dependent CKD, examining cross-sectional associations with appetite and sarcopenic measures, and longitudinal associations with CKD progression and all-cause mortality. Participants were drawn from the NURTuRE-CKD study, a prospective, multicenter cohort study of 2996 people with non-dialysis-dependent CKD recruited from 16 nephrology centers in the UK from July 2017 to September 2019. Study details have been previously published elsewhere.23 Biomarkers, clinical, and demographic information were collected at the baseline study visit. Biological sex, male or female, was self-reported based on sex assigned at birth. Serial eGFR measurements, dialysis initiation, and mortality data were provided by the UK Renal Registry through December 31, 2022. Ethics All participants provided written informed consent. The study was approved by the South Central–Berkshire Research Ethics Committee (IRAS project ID: 211479) and abides by the principles of the Declaration of Helsinki. Assay Measurements Exposure Serum GDF-15 was analyzed centrally at Geneva University Hospitals using a routine Roche cobas 8000 analyzer series. Intra- and inter-assay imprecision were determined with 84 separate internal quality control samples. Intra-assay imprecision was assessed at high and medium concentration levels, while inter-assay imprecision was evaluated at high and low concentration levels. Values outside the analytical range, exceeding the upper limit of quantification or below the lower limit of quantification, were set to the respective limit. Covariates Cystatin C, creatinine, and high-sensitivity C-reactive protein (CRP), as well as urinary albumin and creatinine, were analyzed centrally at Geneva University Hospitals using a routine Roche cobas 8000 analyzer series. All other laboratory values were obtained from local hospital results at the baseline study visit. Creatinine-based estimated GFR (eGFR) was calculated using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation24 without the ethnicity variable, as recommended by the National Institute for Health and Care Excellence in 2021.25 Cystatin C-based eGFR was calculated using the 2012 CKD-EPI equation.26 Outcome Measures The primary outcome was self-reported appetite at baseline, assessed with the Integrated Palliative Care Outcome Score for Renal item: poor appetite.27 Participants were asked to rate their appetite over the past week using the following 5-point scale: 0 = not at all (i.e., no reduction in appetite), 1 = slightly, 2 = moderately, 3 = severely, and 4 = overwhelmingly; higher scores indicate poorer appetite. Secondary outcomes were:1.CKD progression, defined as a ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or initiation of dialysis persisting for ≥ 28 days;2.All-cause mortality before the start of dialysis;3.Anthropometric and functional measures, including:i.Handgrip strength (kg), measured on the dominant arm using a Takei 5401 handgrip digital dynamometer (Takei Scientific Instruments Co., Ltd., Tokyo, Japan) in a standing position or, if not possible, while sitting upright with the elbow extended. Grip width was adjusted until the second joint of the participant’s forefinger was flexed to 90°. Participants were instructed to grip the dynamometer, exert full force without letting their arm touch their body, and then relax. For reference, reduced muscle function is defined as < 27 kg in males and < 25 kg in females28;ii.Creatinine muscle index (CMI), expressed as mg/day per 1.73 m2 (an estimate of glomerular filtration of creatinine and a surrogate for muscle mass calculated as serum creatinine concentration x eGFRcystatin). For reference, the median CMI in one elderly cohort was 824 mg/day per 1.73 m2. Lower levels are associated with frailty components, sarcopenia, increased all-cause mortality, and lower thigh muscle mass on computed tomography scans.29, 30, 31iii.Body mass index (BMI). 1.CKD progression, defined as a ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or initiation of dialysis persisting for ≥ 28 days; CKD progression, defined as a ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or initiation of dialysis persisting for ≥ 28 days; 2.All-cause mortality before the start of dialysis; All-cause mortality before the start of dialysis; 3.Anthropometric and functional measures, including:i.Handgrip strength (kg), measured on the dominant arm using a Takei 5401 handgrip digital dynamometer (Takei Scientific Instruments Co., Ltd., Tokyo, Japan) in a standing position or, if not possible, while sitting upright with the elbow extended. Grip width was adjusted until the second joint of the participant’s forefinger was flexed to 90°. Participants were instructed to grip the dynamometer, exert full force without letting their arm touch their body, and then relax. For reference, reduced muscle function is defined as < 27 kg in males and < 25 kg in females28;ii.Creatinine muscle index (CMI), expressed as mg/day per 1.73 m2 (an estimate of glomerular filtration of creatinine and a surrogate for muscle mass calculated as serum creatinine concentration x eGFRcystatin). For reference, the median CMI in one elderly cohort was 824 mg/day per 1.73 m2. Lower levels are associated with frailty components, sarcopenia, increased all-cause mortality, and lower thigh muscle mass on computed tomography scans.29, 30, 31iii.Body mass index (BMI). Anthropometric and functional measures, including:i.Handgrip strength (kg), measured on the dominant arm using a Takei 5401 handgrip digital dynamometer (Takei Scientific Instruments Co., Ltd., Tokyo, Japan) in a standing position or, if not possible, while sitting upright with the elbow extended. Grip width was adjusted until the second joint of the participant’s forefinger was flexed to 90°. Participants were instructed to grip the dynamometer, exert full force without letting their arm touch their body, and then relax. For reference, reduced muscle function is defined as < 27 kg in males and < 25 kg in females28;ii.Creatinine muscle index (CMI), expressed as mg/day per 1.73 m2 (an estimate of glomerular filtration of creatinine and a surrogate for muscle mass calculated as serum creatinine concentration x eGFRcystatin). For reference, the median CMI in one elderly cohort was 824 mg/day per 1.73 m2. Lower levels are associated with frailty components, sarcopenia, increased all-cause mortality, and lower thigh muscle mass on computed tomography scans.29, 30, 31iii.Body mass index (BMI). i.Handgrip strength (kg), measured on the dominant arm using a Takei 5401 handgrip digital dynamometer (Takei Scientific Instruments Co., Ltd., Tokyo, Japan) in a standing position or, if not possible, while sitting upright with the elbow extended. Grip width was adjusted until the second joint of the participant’s forefinger was flexed to 90°. Participants were instructed to grip the dynamometer, exert full force without letting their arm touch their body, and then relax. For reference, reduced muscle function is defined as < 27 kg in males and < 25 kg in females28; Handgrip strength (kg), measured on the dominant arm using a Takei 5401 handgrip digital dynamometer (Takei Scientific Instruments Co., Ltd., Tokyo, Japan) in a standing position or, if not possible, while sitting upright with the elbow extended. Grip width was adjusted until the second joint of the participant’s forefinger was flexed to 90°. Participants were instructed to grip the dynamometer, exert full force without letting their arm touch their body, and then relax. For reference, reduced muscle function is defined as < 27 kg in males and < 25 kg in females28; ii.Creatinine muscle index (CMI), expressed as mg/day per 1.73 m2 (an estimate of glomerular filtration of creatinine and a surrogate for muscle mass calculated as serum creatinine concentration x eGFRcystatin). For reference, the median CMI in one elderly cohort was 824 mg/day per 1.73 m2. Lower levels are associated with frailty components, sarcopenia, increased all-cause mortality, and lower thigh muscle mass on computed tomography scans.29, 30, 31 Creatinine muscle index (CMI), expressed as mg/day per 1.73 m2 (an estimate of glomerular filtration of creatinine and a surrogate for muscle mass calculated as serum creatinine concentration x eGFRcystatin). For reference, the median CMI in one elderly cohort was 824 mg/day per 1.73 m2. Lower levels are associated with frailty components, sarcopenia, increased all-cause mortality, and lower thigh muscle mass on computed tomography scans.29, 30, 31 iii.Body mass index (BMI). Body mass index (BMI). Participants were censored at the last follow-up time (December 31, 2022). Statistical Analysis Categorical variables are expressed as n (%) and were compared using the chi-squared test. Continuous variables are expressed as median (interquartile range) and were compared using the Kruskal–Wallis test. As GDF-15 concentrations were right-skewed, values were log2-transformed for modeling; effect estimates are reported per doubling of GDF-15. Logistic regression was used to examine the association between GDF-15 and poor appetite, with the Integrated Palliative Care Outcome Score for Renal poor appetite item dichotomized as any poor appetite (scores 1–4) versus none (score 0). This binary outcome was used for the primary analysis because relatively few participants reported severe appetite symptoms at the higher Integrated Palliative Care Outcome Score for Renal categories. To assess whether this dichotomization resulted in a loss of information, ordinal logistic regression was also performed as a sensitivity analysis using the original 5-level appetite score. Models were adjusted for markers of kidney function (eGFR and urea), nutritional and metabolic status (albumin, phosphate, and calcium), systemic inflammation (CRP), comorbidity burden (diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting), and smoking status, selected a priori as factors plausibly associated with both circulating GDF-15 concentrations and appetite. These adjustments were intended to assess whether the association between GDF-15 and appetite was independent of kidney disease severity, inflammation, and comorbidity. Multicollinearity was assessed using the variance inflation factor (VIF). Only urea had a VIF > 1.1 (VIF = 2.56); however, given all VIFs were < 5, all covariates were included in the model.32 In separate analyses, the association between GDF-15 and poor appetite was compared with those of other biomarkers (CRP, phosphate, urine albumin–creatinine ratio [UACR], albumin, eGFR, and calcium), each scaled by 1 standard deviation (SD) to enable effect-size comparisons. This was assessed in univariable models estimating individual biomarker associations and in multivariable models adjusting for all biomarkers simultaneously to enable direct comparison of their independent associations with poor appetite. Cox proportional hazards models were used to examine the association between GDF-15 and CKD progression and all-cause mortality. For CKD progression, models were adjusted for the components of the Kidney Failure Risk Equation (UACR, eGFR, age, and sex). For all-cause mortality, models were adjusted for age, sex, eGFR, UACR, CRP, urea, comorbidity burden (diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting), and smoking status. These adjustments were selected a priori to account for established clinical factors associated with disease severity and prognosis, and to assess whether associations with GDF-15 were independent of kidney function, albuminuria, inflammation, and comorbidity, rather than to infer causal effects. GDF-15 and other continuous biochemical variables were log-transformed. Participants with missing covariate data were excluded from the modeling analyses. Interaction analyses were performed to assess whether the association between GDF-15 and CKD progression or mortality differed according to baseline appetite status, using a multiplicative interaction term between log2-transformed GDF-15 and binary poor appetite status. To further assess the association between of GDF-15 and reduced appetite independent of eGFR, the above logistic regression and Cox proportional hazards models were applied within eGFR strata (> 45, 30–45, and < 30 ml/min per 1.73 m2). Given that kidney function was accounted for through stratification by eGFR category, eGFR and urea were not included as covariates in this particular analysis. Because higher GDF-15 levels may be associated with reduced muscle mass, which can affect the accuracy of creatinine-based eGFR, we repeated the analyses using cystatin C–based eGFR as a sensitivity analysis. To assess potential nonlinear associations, GDF-15 was categorized into quartiles. Multivariable logistic regression (poor appetite) and Cox proportional hazards models (CKD progression and all-cause mortality) used quartile 1 (Q1) as the reference with the same covariates as above. For time-to-event outcomes, Kaplan–Meier curves by quartile were compared using the log-rank test. To further evaluate the shape of the association between GDF-15 and longitudinal outcomes, restricted cubic spline (RCS) analyses were performed using Cox proportional hazards models. Log2-transformed GDF-15 was modeled using RCS with three knots. Models were adjusted using the same covariates as the primary adjusted Cox regression analyses for each outcome. Evidence of nonlinearity was assessed using a Wald test of the nonlinear spline term. Model fit was compared between the linear Cox model and the RCS model using the Bayesian Information Criterion (BIC). Spearmans rank correlation coefficient was used to assess the correlation between GDF-15 and creatinine-based and cystatin C–based eGFR, as well as handgrip strength (kg), CMI (mg/day per 1.73 m2), and BMI (kg/m2). Spearman’s rank correlation was used to describe the unadjusted associations, as this does not assume normally distributed variables or a linear relationship. Linear regression models were then fitted to evaluate the association between log2-transformed GDF-15 levels and handgrip strength, CMI, and BMI. This enabled adjustment for relevant covariates of age, sex, eGFRcystatin C, urea, UACR, CRP, diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting, and smoking status. CMI was not adjusted for eGFRcystatin C, as it is a component of the metric. Annual eGFR slope (mL/min per 1.73 m2 per year) was estimated in participants with serial eGFR measurements using linear mixed-effects models with follow-up time as a fixed effect and participant-specific random intercepts and slopes. A P-value < 0.05 was considered statistically significant. All statistical analyses were performed using RStudio version 2023.09.1. Figures were produced using RStudio and GraphPad Prism. Results Description of the Cohort Of the 2996 participants, 2929 had GDF-15 measured at baseline, of whom 1722 (59%) were male; the median age (25th to 75th percentile) was 66 (53–74) years, and the median creatinine-based eGFR was 34 (24–47) ml/min per 1.73 m2. Among these, 2865 completed the appetite questionnaire, 2826 had serial eGFR measurements, 2856 had BMI data available, and 2867 had handgrip strength available. Mortality and creatinine muscle index (CMI) data were available for all 2929 participants (Supplementary Figure S1). GDF-15 Distribution and Precision Median serum GDF-15 concentration was 2503 (1605, 3851) pg/ml. GDF-15 demonstrated excellent precision, with inter-assay and intra-assay coefficients of variation of < 1% and < 1.3%, respectively. Of the 2929 measurements, only 2 (0.07%) exceeded the upper limit of quantification and 10 (0.34%) were below the lower limit of quantification. Associations of GDF-15 With Appetite Overall, 786 (27%) individuals reported poor appetite; the distribution of poor appetite by CKD stage, estimated by both creatinine and cystatin C, is shown in Table 1. Poor appetite varied by CKD stage and was more prevalent in categories G4 and G5 (as estimated by both creatinine and cystatin C).Table 1GDF-15 levels and prevalence of poor appetite by KDIGO CKD categoryCKD categoryG1 n = 53G2 n = 246G3a n = 486G3b n = 936G4 n = 1055G5 n = 89P-valueeGFR creatinine (ml/min per 1.73 m2)GDF-15 (pg/ml)812 (548, 1315)1351 (939, 2079)1608 (1099, 2342)2364 (1691, 3516)3344 (2377, 4637)5457 (3770, 7582)< 0.001Poor appetite (%)15 (28%)70 (28%)105 (22%)235 (25%)323 (31%)38 (43%)< 0.001eGFR cystatin C (ml/min per 1.73 m2)n = 29n = 158n = 342n = 856n = 1320n = 160GDF-15 (pg/ml)612 (488, 784)959 (730, 1310)1347 (987, 1928)2041 (1481, 2841)3214 (2354, 4,486)5629 (4048, 8036)< 0.001Poor appetite (%)10 (34%)33 (21%)56 (16%)210 (25%)392 (30%)85 (53%)< 0.001CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; IPOS, Integrated Palliative Care Outcome Scale; IQR, interquartile range; KDIGO, Kidney Disease: Improving Global Outcomes.CKD stage according to KDIGO glomerular filtration rate (G) categories using the CKD-EPI 2012 creatinine (race-free) and the CKD-EPI 2012 cystatin C. Appetite was assessed using the IPOS-renal “poor appetite” item(0 = not at all; 1–4 = any degree of poor appetite). GDF-15 concentration levels are presented as median (interquartile range). Table 1GDF-15 levels and prevalence of poor appetite by KDIGO CKD categoryCKD categoryG1 n = 53G2 n = 246G3a n = 486G3b n = 936G4 n = 1055G5 n = 89P-valueeGFR creatinine (ml/min per 1.73 m2)GDF-15 (pg/ml)812 (548, 1315)1351 (939, 2079)1608 (1099, 2342)2364 (1691, 3516)3344 (2377, 4637)5457 (3770, 7582)< 0.001Poor appetite (%)15 (28%)70 (28%)105 (22%)235 (25%)323 (31%)38 (43%)< 0.001eGFR cystatin C (ml/min per 1.73 m2)n = 29n = 158n = 342n = 856n = 1320n = 160GDF-15 (pg/ml)612 (488, 784)959 (730, 1310)1347 (987, 1928)2041 (1481, 2841)3214 (2354, 4,486)5629 (4048, 8036)< 0.001Poor appetite (%)10 (34%)33 (21%)56 (16%)210 (25%)392 (30%)85 (53%)< 0.001CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; IPOS, Integrated Palliative Care Outcome Scale; IQR, interquartile range; KDIGO, Kidney Disease: Improving Global Outcomes.CKD stage according to KDIGO glomerular filtration rate (G) categories using the CKD-EPI 2012 creatinine (race-free) and the CKD-EPI 2012 cystatin C. Appetite was assessed using the IPOS-renal “poor appetite” item(0 = not at all; 1–4 = any degree of poor appetite). GDF-15 concentration levels are presented as median (interquartile range). GDF-15 levels and prevalence of poor appetite by KDIGO CKD category CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; IPOS, Integrated Palliative Care Outcome Scale; IQR, interquartile range; KDIGO, Kidney Disease: Improving Global Outcomes. CKD stage according to KDIGO glomerular filtration rate (G) categories using the CKD-EPI 2012 creatinine (race-free) and the CKD-EPI 2012 cystatin C. Appetite was assessed using the IPOS-renal “poor appetite” item(0 = not at all; 1–4 = any degree of poor appetite). GDF-15 concentration levels are presented as median (interquartile range). Serum GDF-15 concentrations were higher in participants who experienced any level of poor appetite, 2350 pg/ml (1505–3601) vs 2965 pg/ml (1934–4591) (P < 0.001). As the severity of self-reported appetite worsened, GDF-15 levels increased (Figure 1): 2350 pg/ml (1505–3601) for score 0 (n = 2079; 73%), 2742 pg/ml (1784–4531) for score 1 (n = 420; 15%), 3092 pg/ml (2109–4796) for score 2 (n = 244; 9%), 3230 pg/ml (2092–4460) for score 3 (n = 93; 3%), and 3178 pg/ml (1879–5526) for score 4 (n = 29; 1%) (P < 0.001). Consistent with this ordinal trend, there was a weak positive Spearman correlation between appetite score and serum GDF-15 concentration (ρ = 0.16; P < 0.001). This relationship is shown as scatter plots on the ordinal and binary scales in Supplementary Figure S2A and B, respectively. Of note, adjusted analyses using untransformed GDF-15 were performed, and the direction of association and statistical inference were unchanged.Figure 1Serum GDF-15 concentrationby self-reported appetite. Box plot of GDF-15 levels per appetite scale. Appetite was assessed via the IPOS-renal item, “poor appetite.” Participants were asked to rate their appetite impairment over the past week using the following 5-point scale: 0 = Not at all, 1 = Slightly, 2 = Moderately, 3 = Severely, 4 = Overwhelmingly. Median circulating GDF-15 concentrations (95% CI) according to appetite rating: 2350 pg/ml (1505–3601) for score 0 (n = 2079; 73%), 2742 pg/ml (1784–4531) for score 1 (n = 420; 15%), 3092 pg/ml (2109–4,796) for score 2 (n = 244; 9%), 3230 pg/ml (2092–4460) for score 3 (n = 93; 3%), and 3178 pg/ml (1879–5526) for score 4 (n = 29; 1%). As the data were not normally distributed, a Kruskal–Wallis test was performed, demonstrating a significant overall difference between groups (P < 0.001). GDF-15, growth differentiation factor-15; IPOS, Integrated Palliative Care Outcome Scale. Serum GDF-15 concentrationby self-reported appetite. Box plot of GDF-15 levels per appetite scale. Appetite was assessed via the IPOS-renal item, “poor appetite.” Participants were asked to rate their appetite impairment over the past week using the following 5-point scale: 0 = Not at all, 1 = Slightly, 2 = Moderately, 3 = Severely, 4 = Overwhelmingly. Median circulating GDF-15 concentrations (95% CI) according to appetite rating: 2350 pg/ml (1505–3601) for score 0 (n = 2079; 73%), 2742 pg/ml (1784–4531) for score 1 (n = 420; 15%), 3092 pg/ml (2109–4,796) for score 2 (n = 244; 9%), 3230 pg/ml (2092–4460) for score 3 (n = 93; 3%), and 3178 pg/ml (1879–5526) for score 4 (n = 29; 1%). As the data were not normally distributed, a Kruskal–Wallis test was performed, demonstrating a significant overall difference between groups (P < 0.001). GDF-15, growth differentiation factor-15; IPOS, Integrated Palliative Care Outcome Scale. In unadjusted analysis, the odds ratio (OR) for poor appetite per doubling of GDF-15 was 1.41 (95% confidence interval [CI], 1.29–1.54). In models adjusted for eGFR, nutritional and metabolic status, inflammation, individual comorbidities, and smoking, the association remained significant (OR, 1.44; 95% CI, 1.28–1.62) (Table 2). This relationship was similarly maintained in both unadjusted and adjusted ordinal logistic regression (Supplementary Table S1).Table 2Odds Ratio and Hazard Ratios of poor appetite, CKD progression, and All-cause mortality per doubling of serum GDF-15 concentrationOutcomeUnadjustedAdjustedPoor appetite, OR (95% CI)1.41 (1.29–1.54)1.44 (1.28–1.62)CKD progression, HR (95% CI)1.68 (1.58–1.78)1.30 (1.18–1.42)All-Cause Mortality, HR (95% CI)2.12 (1.98–2.26)1.72 (1.58–1.89)CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; HR, hazard ratio; IPOS, Integrated Palliative Care Outcome Scale; KFRE, Kidney Failure Risk Equation; OR, odds ratio; UACR, urinary albumin-to-creatinine ratio.Appetite was assessed using the IPOS-renal item “poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as a ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or dialysis for ≥ 28 days. All-cause mortality was defined as death prior to dialysis initiation.Odds ratios (OR) with 95% confidence intervals (CI) were estimated for poor appetite using logistic regression adjusted for log-transformed albumin, phosphate, calcium, CRP, urea, and eGFR, smoking status and individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting.Hazard ratios (HR) and 95% CIs for CKD progression and mortality were estimated using Cox proportional hazards models. Models for CKD progression were adjusted for log-transformed UACR, eGFR, age, and sex; mortality models were adjusted for age, sex, eGFR, log-transformed ACR, CRP, Charlson comorbidity index, and smoking status. Table 2Odds Ratio and Hazard Ratios of poor appetite, CKD progression, and All-cause mortality per doubling of serum GDF-15 concentrationOutcomeUnadjustedAdjustedPoor appetite, OR (95% CI)1.41 (1.29–1.54)1.44 (1.28–1.62)CKD progression, HR (95% CI)1.68 (1.58–1.78)1.30 (1.18–1.42)All-Cause Mortality, HR (95% CI)2.12 (1.98–2.26)1.72 (1.58–1.89)CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; HR, hazard ratio; IPOS, Integrated Palliative Care Outcome Scale; KFRE, Kidney Failure Risk Equation; OR, odds ratio; UACR, urinary albumin-to-creatinine ratio.Appetite was assessed using the IPOS-renal item “poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as a ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or dialysis for ≥ 28 days. All-cause mortality was defined as death prior to dialysis initiation.Odds ratios (OR) with 95% confidence intervals (CI) were estimated for poor appetite using logistic regression adjusted for log-transformed albumin, phosphate, calcium, CRP, urea, and eGFR, smoking status and individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting.Hazard ratios (HR) and 95% CIs for CKD progression and mortality were estimated using Cox proportional hazards models. Models for CKD progression were adjusted for log-transformed UACR, eGFR, age, and sex; mortality models were adjusted for age, sex, eGFR, log-transformed ACR, CRP, Charlson comorbidity index, and smoking status. Odds Ratio and Hazard Ratios of poor appetite, CKD progression, and All-cause mortality per doubling of serum GDF-15 concentration CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; HR, hazard ratio; IPOS, Integrated Palliative Care Outcome Scale; KFRE, Kidney Failure Risk Equation; OR, odds ratio; UACR, urinary albumin-to-creatinine ratio. Appetite was assessed using the IPOS-renal item “poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as a ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or dialysis for ≥ 28 days. All-cause mortality was defined as death prior to dialysis initiation. Odds ratios (OR) with 95% confidence intervals (CI) were estimated for poor appetite using logistic regression adjusted for log-transformed albumin, phosphate, calcium, CRP, urea, and eGFR, smoking status and individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting. Hazard ratios (HR) and 95% CIs for CKD progression and mortality were estimated using Cox proportional hazards models. Models for CKD progression were adjusted for log-transformed UACR, eGFR, age, and sex; mortality models were adjusted for age, sex, eGFR, log-transformed ACR, CRP, Charlson comorbidity index, and smoking status. When GDF-15 was compared with other biomarkers, it demonstrated the strongest association with a relative risk of poor appetite per 1-SD increase (Figure 2). This was the case in both unadjusted and adjusted analyses (Supplementary Table S2).Figure 2Comparative strength of biomarker associations with poor appetite. Forest plot showing aORs with 95% CIs for the association between each biomarker and poor appetite. Appetite was assessed using the IPOS-Renal item (“poor appetite”) and dichotomised as any degree (scores 1–4) vs none (0). All predictors were log-transformed and standardised; estimates represent the aOR per 1-SD higher biomarker level. The vertical dotted line indicates aOR = 1. aOR, adjusted odds ratio; CI, confidence interval; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; UACR, urinary albumin-to-creatinine ratio. Comparative strength of biomarker associations with poor appetite. Forest plot showing aORs with 95% CIs for the association between each biomarker and poor appetite. Appetite was assessed using the IPOS-Renal item (“poor appetite”) and dichotomised as any degree (scores 1–4) vs none (0). All predictors were log-transformed and standardised; estimates represent the aOR per 1-SD higher biomarker level. The vertical dotted line indicates aOR = 1. aOR, adjusted odds ratio; CI, confidence interval; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; UACR, urinary albumin-to-creatinine ratio. GDF-15 levels showed a weak positive correlation with urine albumin-to-creatinine ratio (UACR) (ρ 0.21; P < 0.001) and systolic blood pressure (ρ = 0.12; P < 0.001). There was a strong negative correlation with both eGFRcreatinine (ρ = −0.55; P <0.001) and eGFRcystatinC(ρ = −0.67; P < 0.001). To further evaluate whether the association of GDF-15 with poor appetite was independent of kidney function, analyses were stratified by eGFR (Table 3). In adjusted models using creatinine-based eGFR, GDF-15 remained associated with poor appetite across all strata. When using cystatin C–based eGFR, the association was also present in the 30–45 and < 30 ml/min per 1.73 m2 strata, but not in the > 45 ml/min per 1.73 m2 group.Table 3Odds Ratio and Hazard Ratios of poor appetite, CKD progression and All-cause mortality per doubling of serum GDF-15 in individual eGFR strataOutcome measureeGFR creatinine (ml/min per 1.73 m2)eGFR cystatin C (ml/min per 1.73 m2)eGFR > 45 (n = 785)eGFR 30–45 (n = 936)eGFR < 30 (n = 1144)eGFR > 45 (n = 529)eGFR 30- 45 (n = 856)eGFR < 30 (n = 1480)Poor appetite, OR (95% CI)1.34 (1.06–1.68)1.39 (1.15–1.69)1.29 (1.07–1.55)1.11 (0.79–1.57)1.47 (1.17–1.84)1.2 (1.03–1.41)CKD progression, HR (95% CI)1.72 (1.32–2.2)1.31 (1.11–1.5)1.04 (0.90–1.2)1.82 (1.26–2.6)1.28 (1.08–1.5)1.09 (0.96–1.2)All-Cause Mortality, HR (95% CI)1.90 (1.54–2.34)1.69 (1.32–2.17)1.92 (1.68–2.21)2.70 (1.70–4.28)1.68 (1.44–1.97)1.66 (1.50–1.84)CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; HR, hazard ratio; IPOS, Integrated Palliative Care Outcome Scale; OR, odds ratio; UACR, urinary albumin-to-creatinine ratio.Appetite was assessed using the IPOS-Renal item “poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or dialysis for ≥ 28 days. All-cause mortality was defined as death prior to dialysis initiation.Odds ratios (OR) with 95% confidence intervals (CI) were estimated for poor appetite using logistic regression adjusted for log-transformed albumin, phosphate, calcium, CRP, eGFR, urea, smoking statusand individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting.Hazard ratios (HR) with 95% CI for CKD progression and mortality were estimated using Cox proportional hazards models. Models for CKD progression were adjusted for log-transformed UACR, eGFR, age, and sex; mortality models were adjusted for age, sex, eGFR, log-transformed UACR, CRP, smoking status, and individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting. Table 3Odds Ratio and Hazard Ratios of poor appetite, CKD progression and All-cause mortality per doubling of serum GDF-15 in individual eGFR strataOutcome measureeGFR creatinine (ml/min per 1.73 m2)eGFR cystatin C (ml/min per 1.73 m2)eGFR > 45 (n = 785)eGFR 30–45 (n = 936)eGFR < 30 (n = 1144)eGFR > 45 (n = 529)eGFR 30- 45 (n = 856)eGFR < 30 (n = 1480)Poor appetite, OR (95% CI)1.34 (1.06–1.68)1.39 (1.15–1.69)1.29 (1.07–1.55)1.11 (0.79–1.57)1.47 (1.17–1.84)1.2 (1.03–1.41)CKD progression, HR (95% CI)1.72 (1.32–2.2)1.31 (1.11–1.5)1.04 (0.90–1.2)1.82 (1.26–2.6)1.28 (1.08–1.5)1.09 (0.96–1.2)All-Cause Mortality, HR (95% CI)1.90 (1.54–2.34)1.69 (1.32–2.17)1.92 (1.68–2.21)2.70 (1.70–4.28)1.68 (1.44–1.97)1.66 (1.50–1.84)CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; HR, hazard ratio; IPOS, Integrated Palliative Care Outcome Scale; OR, odds ratio; UACR, urinary albumin-to-creatinine ratio.Appetite was assessed using the IPOS-Renal item “poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or dialysis for ≥ 28 days. All-cause mortality was defined as death prior to dialysis initiation.Odds ratios (OR) with 95% confidence intervals (CI) were estimated for poor appetite using logistic regression adjusted for log-transformed albumin, phosphate, calcium, CRP, eGFR, urea, smoking statusand individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting.Hazard ratios (HR) with 95% CI for CKD progression and mortality were estimated using Cox proportional hazards models. Models for CKD progression were adjusted for log-transformed UACR, eGFR, age, and sex; mortality models were adjusted for age, sex, eGFR, log-transformed UACR, CRP, smoking status, and individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting. Odds Ratio and Hazard Ratios of poor appetite, CKD progression and All-cause mortality per doubling of serum GDF-15 in individual eGFR strata CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; HR, hazard ratio; IPOS, Integrated Palliative Care Outcome Scale; OR, odds ratio; UACR, urinary albumin-to-creatinine ratio. Appetite was assessed using the IPOS-Renal item “poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or dialysis for ≥ 28 days. All-cause mortality was defined as death prior to dialysis initiation. Odds ratios (OR) with 95% confidence intervals (CI) were estimated for poor appetite using logistic regression adjusted for log-transformed albumin, phosphate, calcium, CRP, eGFR, urea, smoking statusand individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting. Hazard ratios (HR) with 95% CI for CKD progression and mortality were estimated using Cox proportional hazards models. Models for CKD progression were adjusted for log-transformed UACR, eGFR, age, and sex; mortality models were adjusted for age, sex, eGFR, log-transformed UACR, CRP, smoking status, and individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting. Associations of GDF-15 With Anthropometric and Functional Measures Table 4 summarizes the relationships between GDF-15 and handgrip strength, CMI, and BMI. There was a negative correlation between GDF-15 and handgrip strength (kg) (ρ = −0.18; P < 0.001) and CMI (mg/day per 1.73 m2) (ρ = −0.40; P < 0.001). However, no association was found between GDF-15 and BMI (ρ = 0.01; P = 0.589). Unadjusted linear regression produced similar results. In adjusted models, a doubling of GDF-15 was associated with a 0.9- kg decrease in handgrip strength and a 52 mg/d per 1.73 m2 reduction in CMI.Table 4Associations of serum GDF-15 concentration with handgrip strength, creatinine muscle index, and body mass indexOutcome measureHandgrip Strength (kg)Creatinine Muscle Index (mg/day per 1.73 m2)Body Mass Index (kg/m2)Effect estimate (95% CI)P valueEffect estimate (95% CI)P valueEffect estimate (95% CI)P-valueSpearman’s correlation coefficient (ρ)−0.18< 0.001−0.40< 0.0010.010.589Unadjusted Linear regression (β)−2.0 (−2.4 to −1.6)< 0.001−95.1 (−103.1 to −87.1)< 0.0010.1 (−0.2 to 0.32)0.488Adjusted Linear regression (β)−0.9 (−1.3 to -0.4)< 0.001−52.0 (−61.1 to −42.8)< 0.001−1.0 (−1.3 to −0.6)< 0.001CI, confidence interval;.CMI, Creatinine muscle index; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; UACR, urinary albumin-to-creatinine ratio.For multivariable linear regression models, adjustments were made for age, sex, eGFR cystatin C, C-reactive protein (CRP), urinary albumin-to-creatinine ratio (UACR), individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting, and smoking status. CMI was not adjusted for eGFR cystatin C, as this is a component of the metric. Table 4Associations of serum GDF-15 concentration with handgrip strength, creatinine muscle index, and body mass indexOutcome measureHandgrip Strength (kg)Creatinine Muscle Index (mg/day per 1.73 m2)Body Mass Index (kg/m2)Effect estimate (95% CI)P valueEffect estimate (95% CI)P valueEffect estimate (95% CI)P-valueSpearman’s correlation coefficient (ρ)−0.18< 0.001−0.40< 0.0010.010.589Unadjusted Linear regression (β)−2.0 (−2.4 to −1.6)< 0.001−95.1 (−103.1 to −87.1)< 0.0010.1 (−0.2 to 0.32)0.488Adjusted Linear regression (β)−0.9 (−1.3 to -0.4)< 0.001−52.0 (−61.1 to −42.8)< 0.001−1.0 (−1.3 to −0.6)< 0.001CI, confidence interval;.CMI, Creatinine muscle index; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; UACR, urinary albumin-to-creatinine ratio.For multivariable linear regression models, adjustments were made for age, sex, eGFR cystatin C, C-reactive protein (CRP), urinary albumin-to-creatinine ratio (UACR), individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting, and smoking status. CMI was not adjusted for eGFR cystatin C, as this is a component of the metric. Associations of serum GDF-15 concentration with handgrip strength, creatinine muscle index, and body mass index CI, confidence interval;.CMI, Creatinine muscle index; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; UACR, urinary albumin-to-creatinine ratio. For multivariable linear regression models, adjustments were made for age, sex, eGFR cystatin C, C-reactive protein (CRP), urinary albumin-to-creatinine ratio (UACR), individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting, and smoking status. CMI was not adjusted for eGFR cystatin C, as this is a component of the metric. Associations of GDF-15 with CKD Progression and All-Cause Mortality Over the median follow-up of 50 (41–56) months, 893 (32%) participants experienced CKD progression, and 527 (18%) died. GDF-15 levels were higher in those experiencing CKD progression (3024 vs 2145 pg/ml; P < 0.001) and mortality (3943 vs. 2241 pg/ml; P < 0.001). For CKD progression, in unadjusted analysis, the hazard ratio (HR) per doubling of GDF-15 was 1.68 (95% CI, 1.58–1.78). In adjusted models, the association persisted with an HR of 1.30 (95% CI 1.18–1.42) (Table 2). For all-cause mortality, the unadjusted HR was 2.12 (95% CI, 1.98–2.26) and adjusted HR was 1.72 (95% CI, 1.58–1.89) (Table 2). There was no statistically significant interaction between GDF-15 and baseline poor appetite for either CKD progression (interaction HR, 0.84; 95% CI, 0.69–1.01; P = 0.060) or mortality (interaction HR, 1.08; 95% CI, 0.88–1.32; P = 0.460). When analyzed within individual eGFR strata (Table 3), adjusted models showed that GDF-15 was independently associated with all-cause mortality within all eGFR levels, estimated by creatinine or cystatin C. For CKD progression, GDF-15 was associated with the outcome in participants with eGFRs of 30–45 and > 45 ml/min per 1.73 m2. Quartile Analysis and Tests of Linearity The cohort was divided into quartiles of GDF-15 (Table 5). Across quartiles Q1–Q4, age, comorbidity prevalence, and smoking increased, whereas BMI did not differ significantly. CRP and UACR increased, whereas eGFR (by creatinine or cystatin C) decreased. Primary renal disease diagnoses by quartile are shown in Supplementary Table S3. Diabetic kidney disease was more prevalent in higher GDF-15 quartiles, whereas glomerulonephritis was more prevalent in lower GDF-15 quartiles. However, this should be interpreted with caution, as primary renal diagnoses differed in their baseline eGFR,33 which correlates strongly with circulating GDF-15. All outcome measures worsened through quartiles Q1–Q4, including muscle function, estimation of muscle mass, appetite, CKD progression, and mortality.Table 5Baseline demographics and outcomes by serum GDF-15 concentration quartilesQuartile (n)Q1 (733)Q2 (732)Q3 (732)Q4 (732)GDF-15 (pg/ml)1153 (905, 1396)2023 (1809, 2247)3055 (2747, 3460)5306 (4414, 7225)Age (yrs)54 (42, 62)64 (52, 72)70 (60, 76)71 (64, 78)Male353 (48)407 (56)454 (62)508 (69)Charlson Comorbidity Index2 (0, 3)3 (2, 4)4 (3, 5)5 (4, 6)Diabetes81 (11)187 (26)282 (39)349 (48)Hypertension564 (80)624 (88)631 (87)633 (87)CABG9 (1.3)24 (3.4)19 (2.6)48 (6.6)MI24 (3.4)58 (8.2)74 (10)116 (16)Stroke10 (1.4)21 (3.0)36 (5.0)43 (5.9)Sytolic blood pressure (mm Hg)133 (122, 146)137 (126, 153)140 (128, 155)139 (126, 153)Smoker291 (40)351 (49)374 (52)426 (59)Albumin (g/l)42 (39, 45)41 (38, 45)40 (37, 44)40 (36, 43)Phosphate (mmol/l)1.1 (0.9, 1.2)1.1 (1.0, 1.2)1.1 (1.0, 1.3)1.2 (1.0, 1.3)Calcium (mmol/l)2.4 (2.3, 2.5)2.4 (2.3, 2.5)2.4 (2.3, 2.4)2.4 (2.3, 2.4)CRP (mg/l)1.8 (0.8, 3.9)2.6 (1.2, 5.4)2.8 (1.2, 5.9)3.4 (1.4, 8.2)eGFR creatinine (ml/min per 1.73 m2)49 (39, 61)36 (27, 46)29 (22, 38)25 (18, 34)eGFR cystatin C (ml/min per 1.73 m2)45 (36, 58)32 (26, 40)25 (20, 32)20 (16, 27)UACR (mg/mmol)9 (2, 64)23 (4, 90)28 (5, 114)44 (7, 157)BMI (kg/m2)28.2 (24.9, 32.1)29.1 (25.6, 33.6)28.7 (25.5, 33.4)28.6 (25.0, 32.6)Creatinine Muscle Index (mg/day per 1.73 m2)942 (778, 1,109)816 (690, 969)753 (639, 894)710 (580, 836)Handgrip strength (kg)29 (22, 39)27 (19, 36)26 (19, 34)25 (18, 32)Poor appetite135 (19%)179 (25%)203 (28%)269 (38%)eGFR slope (ml/min per 1.73 m2/yr)−1.56 (−3.12, −0.31)−1.93 (−3.67, −0.58)−2.20 (−3.84, −0.76)−2.26 (−4.05, −0.80)CKD progression115 (16%)207 (28%)284 (40%)287 (44%)All-cause mortality26 (3.5%)78 (11%)147 (20%)276 (38%)Follow-up Time (mos)52 (47, 57)51 (44, 56)48 (39, 55)41 (23, 52)BMI, body mass index; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; MI, myocardial infarction; UACR, urinary albumin-to-creatinine ratio.Appetite was assessed using the IPOS-Renal item' poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as a ≥40% decline in eGFR, incident eGFR <15 ml/min/1.73 m2, or dialysis lasting ≥28 days. All-cause mortality was defined as death prior to dialysis initiation. Smoking included current or ex-smokers.Missing data from the 2926: diabetes 58, hypertension 58, CABG 58, MI 58, Stroke 58, systolic blood pressure 94, smoker 38, albumin 186, phosphate 226, calcium 258, CRP 3, UACR 246, BMI 76, HGS 62, appetite 64, CKE 103. Table 5Baseline demographics and outcomes by serum GDF-15 concentration quartilesQuartile (n)Q1 (733)Q2 (732)Q3 (732)Q4 (732)GDF-15 (pg/ml)1153 (905, 1396)2023 (1809, 2247)3055 (2747, 3460)5306 (4414, 7225)Age (yrs)54 (42, 62)64 (52, 72)70 (60, 76)71 (64, 78)Male353 (48)407 (56)454 (62)508 (69)Charlson Comorbidity Index2 (0, 3)3 (2, 4)4 (3, 5)5 (4, 6)Diabetes81 (11)187 (26)282 (39)349 (48)Hypertension564 (80)624 (88)631 (87)633 (87)CABG9 (1.3)24 (3.4)19 (2.6)48 (6.6)MI24 (3.4)58 (8.2)74 (10)116 (16)Stroke10 (1.4)21 (3.0)36 (5.0)43 (5.9)Sytolic blood pressure (mm Hg)133 (122, 146)137 (126, 153)140 (128, 155)139 (126, 153)Smoker291 (40)351 (49)374 (52)426 (59)Albumin (g/l)42 (39, 45)41 (38, 45)40 (37, 44)40 (36, 43)Phosphate (mmol/l)1.1 (0.9, 1.2)1.1 (1.0, 1.2)1.1 (1.0, 1.3)1.2 (1.0, 1.3)Calcium (mmol/l)2.4 (2.3, 2.5)2.4 (2.3, 2.5)2.4 (2.3, 2.4)2.4 (2.3, 2.4)CRP (mg/l)1.8 (0.8, 3.9)2.6 (1.2, 5.4)2.8 (1.2, 5.9)3.4 (1.4, 8.2)eGFR creatinine (ml/min per 1.73 m2)49 (39, 61)36 (27, 46)29 (22, 38)25 (18, 34)eGFR cystatin C (ml/min per 1.73 m2)45 (36, 58)32 (26, 40)25 (20, 32)20 (16, 27)UACR (mg/mmol)9 (2, 64)23 (4, 90)28 (5, 114)44 (7, 157)BMI (kg/m2)28.2 (24.9, 32.1)29.1 (25.6, 33.6)28.7 (25.5, 33.4)28.6 (25.0, 32.6)Creatinine Muscle Index (mg/day per 1.73 m2)942 (778, 1,109)816 (690, 969)753 (639, 894)710 (580, 836)Handgrip strength (kg)29 (22, 39)27 (19, 36)26 (19, 34)25 (18, 32)Poor appetite135 (19%)179 (25%)203 (28%)269 (38%)eGFR slope (ml/min per 1.73 m2/yr)−1.56 (−3.12, −0.31)−1.93 (−3.67, −0.58)−2.20 (−3.84, −0.76)−2.26 (−4.05, −0.80)CKD progression115 (16%)207 (28%)284 (40%)287 (44%)All-cause mortality26 (3.5%)78 (11%)147 (20%)276 (38%)Follow-up Time (mos)52 (47, 57)51 (44, 56)48 (39, 55)41 (23, 52)BMI, body mass index; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; MI, myocardial infarction; UACR, urinary albumin-to-creatinine ratio.Appetite was assessed using the IPOS-Renal item' poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as a ≥40% decline in eGFR, incident eGFR <15 ml/min/1.73 m2, or dialysis lasting ≥28 days. All-cause mortality was defined as death prior to dialysis initiation. Smoking included current or ex-smokers.Missing data from the 2926: diabetes 58, hypertension 58, CABG 58, MI 58, Stroke 58, systolic blood pressure 94, smoker 38, albumin 186, phosphate 226, calcium 258, CRP 3, UACR 246, BMI 76, HGS 62, appetite 64, CKE 103. Baseline demographics and outcomes by serum GDF-15 concentration quartiles BMI, body mass index; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; MI, myocardial infarction; UACR, urinary albumin-to-creatinine ratio. Appetite was assessed using the IPOS-Renal item' poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as a ≥40% decline in eGFR, incident eGFR <15 ml/min/1.73 m2, or dialysis lasting ≥28 days. All-cause mortality was defined as death prior to dialysis initiation. Smoking included current or ex-smokers. Missing data from the 2926: diabetes 58, hypertension 58, CABG 58, MI 58, Stroke 58, systolic blood pressure 94, smoker 38, albumin 186, phosphate 226, calcium 258, CRP 3, UACR 246, BMI 76, HGS 62, appetite 64, CKE 103. The risk of adverse outcomes associated with increasing GDF-15 quartiles relative to Q1 was examined in both unadjusted and adjusted analyses (Table 6). Across all outcomes, risk increased across the quartiles. Those in Q4 were almost threefold more likely to experience worse appetite compared with Q1 (OR, 2.79; 95% CI, 2.02–3.88).Table 6Odds Ratio and Hazard Ratios of poor appetite, CKD progression, and all-cause mortality across quartiles of serum GDF-15 concentrationOutcome measureUnadjustedAdjustedQ2Q3Q4Q2Q3Q4Appetite (OR, 95% CI)1.46 (1.13–1.88)1.72 (1.34–2.21)2.67 (2.10–3.41)1.48 (1.10–1.98)1.81 (1.33–2.46)2.79 (2.02–3.88)CKD progression (HR, 95% CI)2.02 (1.61–2.54)3.32 (2.67–4.12)4.44 (3.58–5.52)1.16 (0.91–1.48)1.50 (1.17–1.92)1.73 (1.34–2.25)All-cause mortality (HR, 95% CI)3.23 (2.07–5.04)6.83 (4.50–10.4)16.0 (10.7–24.0)2.30 (1.41–3.77)3.79 (2.34–6.12)7.45 (4.63–12.0)CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; HR, hazard ratio; OR, odds ratio; UACR, urinary albumin-to-creatinine ratio.Quartilesof GDF-15 from Q1 to Q4. Median (interquartile range) GDF-15 levels are as follows: Q1, 1153 (905, 1,396) pg/ml; Q2, 2023 (1809, 2247) pg/ml; Q3, 3055 (2747, 3460) pg/ml; and Q4, 5306 (4414, 7225) pg/ml. The risk of events for Q2, Q3, and Q4 was compared to Q1. Appetite was assessed using the IPOS-renal item “poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as a ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or dialysis for ≥ 28 days. All-cause mortality was defined as death before dialysis initiation.OR with 95% CI were estimated for poor appetite using logistic regression adjusted for log-transformed albumin, phosphate, calcium, CRP, urea, eGFR, smoking statusand individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting.HR with 95% CI for CKD progression and mortality were estimated using Cox proportional hazards models. Models for CKD progression were adjusted for log-transformed UACR, eGFR, age, and sex. Mortality models were adjusted for age, sex, eGFR, log-transformed UACR, urea, CRP, smoking statusand individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting. Table 6Odds Ratio and Hazard Ratios of poor appetite, CKD progression, and all-cause mortality across quartiles of serum GDF-15 concentrationOutcome measureUnadjustedAdjustedQ2Q3Q4Q2Q3Q4Appetite (OR, 95% CI)1.46 (1.13–1.88)1.72 (1.34–2.21)2.67 (2.10–3.41)1.48 (1.10–1.98)1.81 (1.33–2.46)2.79 (2.02–3.88)CKD progression (HR, 95% CI)2.02 (1.61–2.54)3.32 (2.67–4.12)4.44 (3.58–5.52)1.16 (0.91–1.48)1.50 (1.17–1.92)1.73 (1.34–2.25)All-cause mortality (HR, 95% CI)3.23 (2.07–5.04)6.83 (4.50–10.4)16.0 (10.7–24.0)2.30 (1.41–3.77)3.79 (2.34–6.12)7.45 (4.63–12.0)CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; HR, hazard ratio; OR, odds ratio; UACR, urinary albumin-to-creatinine ratio.Quartilesof GDF-15 from Q1 to Q4. Median (interquartile range) GDF-15 levels are as follows: Q1, 1153 (905, 1,396) pg/ml; Q2, 2023 (1809, 2247) pg/ml; Q3, 3055 (2747, 3460) pg/ml; and Q4, 5306 (4414, 7225) pg/ml. The risk of events for Q2, Q3, and Q4 was compared to Q1. Appetite was assessed using the IPOS-renal item “poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as a ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or dialysis for ≥ 28 days. All-cause mortality was defined as death before dialysis initiation.OR with 95% CI were estimated for poor appetite using logistic regression adjusted for log-transformed albumin, phosphate, calcium, CRP, urea, eGFR, smoking statusand individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting.HR with 95% CI for CKD progression and mortality were estimated using Cox proportional hazards models. Models for CKD progression were adjusted for log-transformed UACR, eGFR, age, and sex. Mortality models were adjusted for age, sex, eGFR, log-transformed UACR, urea, CRP, smoking statusand individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting. Odds Ratio and Hazard Ratios of poor appetite, CKD progression, and all-cause mortality across quartiles of serum GDF-15 concentration CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; HR, hazard ratio; OR, odds ratio; UACR, urinary albumin-to-creatinine ratio. Quartilesof GDF-15 from Q1 to Q4. Median (interquartile range) GDF-15 levels are as follows: Q1, 1153 (905, 1,396) pg/ml; Q2, 2023 (1809, 2247) pg/ml; Q3, 3055 (2747, 3460) pg/ml; and Q4, 5306 (4414, 7225) pg/ml. The risk of events for Q2, Q3, and Q4 was compared to Q1. Appetite was assessed using the IPOS-renal item “poor appetite” (0 = not at all; 1–4 = any degree of poor appetite). CKD progression was defined as a ≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or dialysis for ≥ 28 days. All-cause mortality was defined as death before dialysis initiation. OR with 95% CI were estimated for poor appetite using logistic regression adjusted for log-transformed albumin, phosphate, calcium, CRP, urea, eGFR, smoking statusand individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting. HR with 95% CI for CKD progression and mortality were estimated using Cox proportional hazards models. Models for CKD progression were adjusted for log-transformed UACR, eGFR, age, and sex. Mortality models were adjusted for age, sex, eGFR, log-transformed UACR, urea, CRP, smoking statusand individual comorbidities including diabetes, hypertension, stroke, myocardial infarction, and coronary artery bypass grafting. In adjusted models, Q3 and Q4 remained significantly associated with CKD progression (Table 6). In the Kaplan-Meier curve analysis (Figure 3a), there appeared to be a stepwise and linear relationship between the quartiles. In restricted cubic spline (RCS) analysis, GDF15 was significantly associated with CKD progression. The shape of the curve was linear (Supplementary Figure S3A); there was no evidence of nonlinearity on Wald testing of the nonlinear spline term (χ2 = 2.12; P = 0.146). In keeping with this, the BIC was lower for the linear Cox model than the RCS model (Supplementary Table S4).Figure 3(a) Time to chronic kidney disease (CKD) progression by GDF-15 quartile 3(b) Time to all-cause mortality by GDF-15 quartile. The curves show the cumulative probability of remaining free of (a) CKD progression and (b) all-cause mortality by baseline GDF-15 quartiles (Q1–Q4). CKD progression is defined as a ≥ 40% decline in eGFR, an incident eGFR < 15 ml/min per 1.73 m2, or the initiation of dialysis lasting 28 days or more. The x-axis shows follow-up time in months, and the y-axis shows the probability of being free from (a) CKD progression (b) all-cause mortality. Patients in higher GDF-15 quartiles had a greater risk of CKD progression and all-cause mortality than those in lower quartiles. Differences between the groups were assessed using the log-rank. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15. (a) Time to chronic kidney disease (CKD) progression by GDF-15 quartile 3(b) Time to all-cause mortality by GDF-15 quartile. The curves show the cumulative probability of remaining free of (a) CKD progression and (b) all-cause mortality by baseline GDF-15 quartiles (Q1–Q4). CKD progression is defined as a ≥ 40% decline in eGFR, an incident eGFR < 15 ml/min per 1.73 m2, or the initiation of dialysis lasting 28 days or more. The x-axis shows follow-up time in months, and the y-axis shows the probability of being free from (a) CKD progression (b) all-cause mortality. Patients in higher GDF-15 quartiles had a greater risk of CKD progression and all-cause mortality than those in lower quartiles. Differences between the groups were assessed using the log-rank. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15. All quartiles remained significantly associated with all-cause mortality in adjusted models (Table 6). Kaplan–Meier curves (Figure 3b) show a relative increase in cumulative incidence of events in higher quartiles. This is also demonstrated in the RCS curve shape (Supplementary Figure 3B), and there was evidence of nonlinearity on Wald testing of the nonlinear spline term (χ2 = 15.76; P < 0.001). Bayesian Information Criterion was also lower for the RCS model over the linear Cox model (Supplementary Table S4). Discussion In this large, multicentre cohort of individuals with non-dialysis CKD, we show that elevated circulating GDF-15 levels are consistently associated with poor appetite, a common yet poorly understood symptom in CKD, and with markers of reduced muscle function and muscle mass. Given that pharmacological inhibition of GDF-15 has been shown to improve appetite and muscle mass in people with cancer, our data provide a rationale for exploring similar therapeutic approaches in CKD.15 Consistent with prior reports, we also observed that higher GDF-15 concentrations were associated with increased risk of CKD progression and all-cause mortality, supporting its utility as a prognostic biomarker in CKD. Anorexia is a prevalent symptom in CKD.1, 2, 3, 4 In this study, over one-quarter of participants reported impaired appetite, and we have previously shown that this negatively affects quality of life.8 Despite this burden, our understanding of its mechanisms and effective treatments remains limited. We hypothesize that GDF-15 mediates CKD-related anorexia, given the elevated circulating levels in CKD19 and the robust evidence for centrally mediated appetite suppression via the hindbrain receptor GFRAL/RET.14 GDF-15 concentrations increased stepwise with worsening self-reported appetite, and after adjustment for confounders, higher GDF-15 remained independently associated with poorer appetite. Consistent with prior reports, the prevalence of poor appetite increased as eGFR fell below 30 ml/min per 1.73 m2, as estimated by both creatinine and cystatin C. As GDF-15 correlated with kidney function, we also stratified analyses by eGFR; the association persisted across strata, supporting its independence from reduced kidney function. Historically, investigators have proposed inflammation and retention of uremic solutes as drivers of anorexia in CKD.6,9,10 We therefore compared GDF-15 with these alternative mediators. In both unadjusted and adjusted models, GDF-15 showed the strongest association with poor appetite. Although CRP and phosphate were also associated with poor appetite, these biomarkers reflect less specific biological processes. As inflammatory signaling can induce GDF-15 expression, CRP may well act as an upstream mediator along the proposed causal pathway linking systemic inflammation to GDF-15–related appetite suppression. Phosphate, by contrast, likely reflects the broader metabolic milieu of advanced CKD and uremic toxicity rather than a specific anorexigenic signaling pathway. Consistent with our observations, a small dialysis cohort (n = 98) reported that higher GDF-15 levels were associated with poorer nutritional status, as indicated by Subjective Global Assessment (SGA).34 That study also assessed several other functional and anthropometric measures but found no significant associations, likely due to the small sample size. Here, we demonstrate that increased GDF-15 is associated with reduced handgrip strength (a measure of muscle function) and CMI (a surrogate marker of muscle mass). The correlation of GDF-15 with eGFRcystatin C was stronger than that with GFRcreatinine, likely due to reduced creatinine generation with reduced muscle mass at higher GDF-15 levels. This observation aligns with findings in people with cancer, where higher GDF-15 levels are associated with weight loss, reduced muscle mass, and decreased strength, and where GDF-15 inhibition improves muscle mass.15,35,36 GDF-15 was associated with BMI only after multivariable adjustment. Although experimental studies show that administration of GDF-15 suppresses appetite and that its inhibition increases food intake,12,13 the relationship between circulating GDF-15 and BMI is not straightforward. Obesity itself elevates GDF-15 via secretion from adipose tissue,37 potentially as a counter-regulatory signal. A Mendelian randomization study found no strong evidence for a causal relationship between circulating GDF-15 levels and BMI. However, the genetic instrument comprised only three single-nucleotide polymorphisms, which may have limited instrument strength and weakened causal inference.38, 39, 40 In a cohort of 381 hemodialysis patients, GDF-15 correlated negatively with BMI; however, GDF-15 was sampled long before dialysis initiation.12 Given this complex relationship and the confounding effects of sarcopenic obesity, measures of sarcopenia may potentially serve as better indicators of the metabolic sequelae of anorexia and elevated GDF-15 than BMI alone. In this study, GDF-15 was also associated with an increased risk of CKD progression and all-cause mortality after multivariable adjustment. This association has been reported previously,20 and we have previously demonstrated that GDF-15 performs well as an independent predictor of these events when compared to other novel biomarkers.41 However, while the causal relationship between GDF-15 and reduced appetite is well supported by a clear biological pathway, experimental mouse models and randomized controlled trial evidence in humans with cancer, its causal relationship with CKD progression and mortality is less clear. Elevated GDF-15 in this context may represent either a pathogenic driver or simply a stress-responsive signal. Transient rises in GDF-15 occur physiologically, such as during exercise and pregnancy (causing hyperemesis),where it may have a beneficial function.42 The biological implications of GDF-15 elevation may vary across pathological states and with chronicity. In murine infection models, for example, circulating GDF-15 levels rise and appear to be tissue-protective, potentially through the modulation of hepatic triglyceride output.43 Specifically, in kidney disease, experimental models of acute kidney injury suggest that initial increases in GDF-15 may be nephroprotective, exerting anti-inflammatory, anti-apoptotic, and Klotho-inducing effects.21 In early ischemic or hypoxic kidney injury, GDF-15 appears to act as an adaptive, tubuloprotective stress-response molecule, with GDF-15-deficient mice developing worse tubular injury and a more pronounced delayed inflammatory response after ischemia. However, systemic GDF-15 administration in these mice was associated with adverse metabolic consequences, including anorexia, weight loss, and cachexia-like wasting, thereby attenuating the beneficial effects and being consistent with observational data linking elevated circulating GDF-15 to adverse outcomes in CKD cohorts.44 A similar context-dependent role for GDF-15 has been described in other chronic inflammatory states, particularly cancer. Acute GDF-15 induction may therefore represent an adaptive, tissue-protective stress response, whereas sustained elevation reflects cellular stress and disease severity, and experimental models of GDF-15-overexpressing tumours demonstrate cachexia and poorer outcomes.42,45 Circulating GDF-15 in healthy adults typically ranges from ∼ 200 to 1200 pg/ml.46,47 In our cohort, those in the lowest quartile (median 1153 [905–1396] pg/ml) had levels similar to the normal range and had a very low mortality rate (3.5%). In quartile-based stratification, those in the highest quartile of GDF-15 (with levels fivefold greater than normal) had more than a sevenfold greater risk of death in adjusted analysis. Similar to what has been previously described, these findings suggest that markedly elevated or sustained GDF-15 may reflect a maladaptive biological state, in which persistent cellular stress and inflammation are associated with increased vulnerability to adverse outcomes. Our observation that circulating GDF-15 and anorexia symptoms rise with advancing CKD suggests that anti–GDF-15 therapy could be investigated as a potential therapy for anorexia in advanced CKD. Reassuringly, in the ponsegromab trial for cancer-associated cachexia, no excess adverse events were observed despite this being a comparatively high-risk cohort,15 supporting feasibility in a vulnerable population. Strengths and Limitations This study was conducted in a large, well-phenotyped multicentre cohort of individuals with non-dialysis dependent CKD, with concurrent assessment of appetite and circulating GDF-15. GDF-15, creatinine and cystatin C were measured centrally under strict quality control, minimizing analytical variability. Inclusion criteria were broad, enhancing generalizability within the non-dialysis-dependent CKD population. CKD progression and mortality outcomes were ascertained through linkage with the national renal registry, reducing the risk of outcome misclassification. Because this is an observational study, causal inferences cannot be made. However, evidence of benefit with a GDF-15 monoclonal antibody in people with cancer strongly supports a causal relationship between elevated GDF-15 and anorexia. The appetite-GDF-15 analysis was not prespecified, introducing the potential for data-driven bias. However, appetite was assessed according to the study protocol using a patient-reported outcome measure before GDF-15 was measured. Muscle mass was not measured directly in this study. Instead, it was estimated using the CMI (mg/d), which has previously been compared with thigh muscle mass on computed tomography imaging.31 As CMI remains an indirect estimate of muscle mass, this should be considered when interpreting our findings. The cohort was derived from secondary care in a single country and was predominantly White (87%), potentially limiting generalizability. Finally, individuals receiving dialysis were excluded because of the study enrolment criteria, and the relevance of these findings to dialysis populations remains uncertain. Conclusion Anorexia is common in CKD and substantially impairs quality of life; however, treatment options are limited. In this multicentre cohort study, elevated circulating GDF-15 levels were independently associated with self-reported poor appetite, markers of sarcopenia, and adverse clinical outcomes of CKD progression and all-cause mortality. Given the availability of a GDF–15 neutralizing monoclonal antibody that improves cachexia, appetite, and muscle mass in people living with cancer and elevated GDF-15, these findings provide a rationale for conducting a clinical trial in people with anorexia and advanced CKD, among whom symptom burden and circulating GDF-15 concentrations are highest. Disclosure MS reports consulting fees for Travere and PureSpring Therapeutics. PAK reports grants or contracts with CSL Vifor, Pharmacosmos, Astellas, Stada, Evotec, and Medice. Consulting fees from AstraZeneca, Boehringer Ingelheim, CSL Vifor, Stada, Pharmacosmos, and Medice. Speaker fees from CSL Vifor, Pharmacosmos, AstraZeneca, Medice, Boehringer Ingelheim, and Bayer. Support for attending meetings from Pharmacosmos, CSL Vifor, and Medice. MWT reports consulting fees from Boehringer Ingelheim, honoraria from Bayer, Wiley Publishers and Boehringer Ingelheim, support to attend a conference from Bayer, royalties from Elsevier as an editor of The Kidney and a leadership role in the International Society of Nephrology. All other authors have no conflicts of interest. Patient Consent All participants provided written informed consent. The study was approved by the South Central— Berkshire Research Ethics Committee, abides by the principles of the Declaration of Helsinki (IRAS project ID: 211479), and is registered at ClinicalTrials.gov (NCT04084145) and includes the current study presented in this manuscript.